Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 109.52M | P/E | - | EPS this Y | -175.90% | Ern Qtrly Grth | - |
| Income | -221.83M | Forward P/E | -2.81 | EPS next Y | 91.00% | 50D Avg Chg | 16.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 138.00% |
| Dividend | N/A | Price/Book | 2.95 | EPS next 5Y | - | 52W High Chg | -17.00% |
| Recommedations | 1.20 | Quick Ratio | 34.99 | Shares Outstanding | 12.82M | 52W Low Chg | 583.00% |
| Insider Own | 0.03% | ROA | -20.32% | Shares Float | 7.30M | Beta | 1.66 |
| Inst Own | 55.08% | ROE | -210.26% | Shares Shorted/Prior | 96.38K/345.14K | Price | 8.54 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,021,642 | Target Price | 23.00 |
| Oper. Margin | - | Earnings Date | Nov 10 | Volume | 98,872 | Change | -6.97% |
About Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.